JY
ACET icon

Jeff Yass’s Adicet Bio ACET Stock Holding History

Jeff Yass’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178K Buy
+20,650
New +$163K ﹤0.01% 12058
2025
Q4 		– Sell
-2,523
Closed -$32.7K – 12190
2025
Q3 		$32.7K Buy
+2,523
New +$29.7K ﹤0.01% 11962
2025
Q2 		– Sell
-28,608
Closed -$346K – 12549
2025
Q1 		$346K Sell
28,608
-1,247
-4% -$17.8K ﹤0.01% 9740
2024
Q4 		$460K Buy
29,855
+7,084
+31% +$134K ﹤0.01% 8884
2024
Q3 		$525K Buy
22,771
+6,402
+39% +$143K ﹤0.01% 8356
2024
Q2 		$317K Buy
16,369
+15,187
+1,285% +$407K ﹤0.01% 9323
2024
Q1 		$44.4K Sell
1,182
-965
-45% -$39.9K ﹤0.01% 11601
2023
Q4 		$64.9K Buy
2,147
+1,366
+175% +$29.8K ﹤0.01% 11597
2023
Q3 		$17.1K Sell
781
-1,894
-71% -$66.9K ﹤0.01% 11638
2023
Q2 		$104K Sell
2,675
-4,332
-62% -$382K ﹤0.01% 10922
2023
Q1 		$646K Buy
7,007
+5,849
+505% +$734K ﹤0.01% 7941
2022
Q4 		$166K Sell
1,158
-2,842
-71% -$709K ﹤0.01% 10379
2022
Q3 		$910K Buy
4,000
+3,318
+487% +$842K ﹤0.01% 6880
2022
Q2 		$159K Buy
+682
New +$150K ﹤0.01% 10952
2022
Q1 		– Sell
-2,576
Closed -$592K – 12875
2021
Q4 		$721K Buy
+2,576
New +$442K ﹤0.01% 8165
2021
Q3 		– Sell
-1,223
Closed -$201K – 12646
2021
Q2 		$201K Sell
1,223
-4,170
-77% -$849K ﹤0.01% 11587
2021
Q1 		$1.13M Buy
5,393
+3,831
+245% +$879K ﹤0.01% 7409
2020
Q4 		$351K Buy
+1,562
New +$320K ﹤0.01% 8955
2020
Q3 		– Sell
-149
Closed -$36K – 10468
2020
Q2 		$36K Sell
149
-340
-70% -$66.8K ﹤0.01% 9827
2020
Q1 		$56K Buy
489
+113
+30% +$16.8K ﹤0.01% 9621
2019
Q4 		$63K Buy
+376
New +$190K ﹤0.01% 9283

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Jeff Yass's ACET Position: Q2 2026 in Review

Jeff Yass opened a new position in Adicet Bio (ACET) in Q2 2026: 20,650 shares worth $178K. The stake represents ﹤0.01% of the portfolio and ranks #12058 among its holdings. This is a return to the name: Jeff Yass previously reported a position in ACET as recently as Q3 2025.

Jeff Yass first reported a position in ACET in Q4 2019 and has held it in 21 quarters since. The position peaked at $1.13M in Q1 2021. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Jeff Yass held 20,650 shares of Adicet Bio worth $178K as of Q2 2026.
  • Adicet Bio was a new Jeff Yass position in Q2 2026.
  • Adicet Bio made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12058 holding.
  • Jeff Yass first reported a position in Adicet Bio in Q4 2019 and has held it in 21 quarters since.
  • Jeff Yass's Adicet Bio position peaked at $1.13M in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.